Gustave Roussy, Cancer Campus, Grand Paris

This study tests the immunotherapy drug nivolumab in 45 children and adults with a rare blood cancer called ALK-positive anaplastic large cell lymphoma that has come back or not responded to treatment. Participants are split into two groups: those with active disease to see if th…

This study was designed to test two immunotherapy drugs, atezolizumab and tiragolumab, in people with advanced lung cancer that has special immune cell clusters called tertiary lymphoid structures. The trial was withdrawn before enrolling any participants, so no results are avail…

This study tests whether a highly focused type of radiation called stereotactic body radiation therapy (SBRT) can delay cancer progression in women with metastatic breast cancer who are starting their first treatment. About 154 participants will receive either standard therapy al…

This study looks at whether removing only the thyroid gland works as well as also removing nearby lymph nodes in people with low-risk thyroid cancer. About 352 patients with small to medium-sized tumors will be randomly assigned to one of the two surgeries. The goal is to see if …

This study tests whether giving the immunotherapy drug pembrolizumab before and after surgery can help prevent head and neck mucosal melanoma from coming back. About 60 adults with resectable tumors will receive pembrolizumab, then surgery and possibly radiation, followed by more…

This early-phase study tests whether adding the targeted drug regorafenib to standard chemotherapy is safe for people with newly diagnosed, widespread Ewing sarcoma. The trial enrolls about 23 patients aged 2 to 49 whose cancer has spread beyond the lungs. The goal is to find a s…

This study tests a new drug called DS-1062a in 100 people with advanced non-small cell lung cancer that has worsened after standard treatments. The drug is given every three weeks and aims to shrink tumors. Researchers will also study how the drug affects the immune system and lo…

This study looks at whether a more intensive follow-up schedule after treatment for head and neck cancer helps people live longer compared to a standard schedule. It involves 197 smokers or heavy drinkers over age 35 who are cancer-free 2-4 months after treatment. The goal is to …

This study was designed for adults with certain types of soft tissue sarcoma that have specific immune cell clusters (TLS) in their tumors. Participants would have received pembrolizumab (immunotherapy) with or without olaparib (a DNA repair blocker) before surgery, followed by m…